Brokerages Set eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) PT at $19.64

Shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRGet Rating) have received an average recommendation of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $19.64.

Several equities research analysts recently commented on the stock. JMP Securities restated a “buy” rating and issued a $8.00 price target on shares of eFFECTOR Therapeutics in a research report on Monday, April 11th. Zacks Investment Research downgraded shares of eFFECTOR Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 10th. Credit Suisse Group reduced their price target on shares of eFFECTOR Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Thursday, March 17th. Finally, Stifel Nicolaus downgraded shares of eFFECTOR Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the company from $20.00 to $6.20 in a research report on Tuesday, January 25th.

In related news, Director Christopher B. Ehrlich bought 5,000 shares of the business’s stock in a transaction on Thursday, February 3rd. The stock was bought at an average price of $5.15 per share, for a total transaction of $25,750.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders acquired 14,000 shares of company stock valued at $70,370.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new position in shares of eFFECTOR Therapeutics during the 3rd quarter worth $187,000. Northern Trust Corp acquired a new position in shares of eFFECTOR Therapeutics during the 4th quarter worth $138,000. Jane Street Group LLC acquired a new position in shares of eFFECTOR Therapeutics during the 3rd quarter worth $257,000. Geode Capital Management LLC acquired a new position in shares of eFFECTOR Therapeutics during the 3rd quarter worth $337,000. Finally, Verition Fund Management LLC acquired a new position in shares of eFFECTOR Therapeutics during the 3rd quarter worth $347,000. Institutional investors own 35.84% of the company’s stock.

EFTR stock opened at $3.32 on Wednesday. eFFECTOR Therapeutics has a 12 month low of $3.26 and a 12 month high of $40.42. The firm has a 50 day simple moving average of $4.26 and a 200 day simple moving average of $6.85. The company has a debt-to-equity ratio of 1.09, a current ratio of 13.30 and a quick ratio of 13.30.

eFFECTOR Therapeutics (NASDAQ:EFTRGet Rating) last released its earnings results on Wednesday, March 16th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.68. As a group, research analysts expect that eFFECTOR Therapeutics will post -1.02 EPS for the current fiscal year.

eFFECTOR Therapeutics Company Profile (Get Rating)

eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.

See Also

Analyst Recommendations for eFFECTOR Therapeutics (NASDAQ:EFTR)

Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.